Bornali Bhattacharjee
Associate Research ScientistCards
About
Titles
Associate Research Scientist
Associate Director, Center for Infection and Immunity
Biography
Dr. Bornali Bhattacharjee, MS, PhD is a Research Associate Scientist at the Department of Immunobiology and the Associate Director at the Center for Infection & Immunity. Her role is to lead, coordinate and manage biomedical research projects that are geared towards understanding the immune trajectories of post-acute infection syndromes.
Her training and research interests lie at the interface of pathogen genomics, evolutionary biology and host-pathogen interaction. She earned her PhD in Molecular Epidemiology & Virology from Indian Statistical Institute & University of Calcutta. Her post-doctoral training was in Viral Genomics & Evolution at University of Massachusetts Medical School.
Last Updated on November 07, 2024.
Departments & Organizations
Education & Training
- PhD
- Indian Statistical Institute & University of Calcutta
- MS
- University of Calcutta, Biochemistry
Research
Publications
2025
Characterization of Postural Orthostatic Tachycardia Syndrome in Long COVID Self-reported Data From the LISTEN Study
AL Mouslmani M, Sawano M, Arun A, Wu Y, Shah R, Kaleem S, Zhou T, Murugiah K, Lu Y, Herrin J, Bishop P, Taub P, Peixoto A, Bhattacharjee B, Iwasaki A, Krumholz H. Characterization of Postural Orthostatic Tachycardia Syndrome in Long COVID Self-reported Data From the LISTEN Study. JACC Advances 2025, 4: 101873. PMID: 40883051, PMCID: PMC12399260, DOI: 10.1016/j.jacadv.2025.101873.Peer-Reviewed Original ResearchSelf-reported diagnosisPostural orthostatic tachycardia syndromeHealth statusSelf-reported long COVIDOrthostatic tachycardia syndromeHealth status of peopleEuroQol visual analog scaleDiagnosis of postural orthostatic tachycardia syndromeOnline observational studyExperiences of peopleStatus of peoplePostacute COVID-19 syndromeChest painVisual analog scaleHigher RatesExcessive fatigueHealth burdenMyalgic encephalomyelitis/chronic fatigue syndromeSocial isolationInternal tremorExercise intoleranceObservational studyFinancial difficultiesAnalog scaleSuicidal thoughtsCerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome
Bastos V, Greene K, Tabachnikova A, Bhattacharjee B, Sjögren P, Bertilson B, Reifert J, Zhang M, Kamath K, Shon J, Gehlhausen J, Guan L, VanElzakker M, Proal A, Bragée B, Iwasaki A. Cerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome. The Journal Of Immunology 2025, 214: 1539-1551. PMID: 40373264, PMCID: PMC12311384, DOI: 10.1093/jimmun/vkaf087.Peer-Reviewed Original ResearchMyalgic encephalomyelitis/chronic fatigue syndromeCerebrospinal fluidImmune phenotypeFatigue syndromeMatched healthy control subjectsAssessed plasma samplesMultiplex analysis of cytokinesHealthy control subjectsAnalysis of cerebrospinal fluidAnalysis of cytokinesTreatment developmentClinical presentationSymptom presentationMultiorgan diseaseInflammatory profileControl subjectsPathophysiological mechanismsMatrix metalloproteinase profilesDisease subgroupsME/CFS participantsClinical questionnaireMatrix metalloproteinasesMetalloproteinase profilesHigh-throughput microarrayPlasma samplesImpact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
Grady C, Bhattacharjee B, Silva J, Jaycox J, Lee L, Silva Monteiro V, Sawano M, Massey D, Caraballo C, Gehlhausen J, Tabachnikova A, Mao T, Lucas C, Peña-Hernandez M, Xu L, Tzeng T, Takahashi T, Herrin J, Güthe D, Akrami A, Assaf G, Davis H, Harris K, McCorkell L, Schulz W, Griffin D, Wei H, Ring A, Guan L, Dela Cruz C, Krumholz H, Iwasaki A. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. Communications Medicine 2025, 5: 163. PMID: 40346201, PMCID: PMC12064684, DOI: 10.1038/s43856-025-00829-3.Peer-Reviewed Original ResearchSpike protein-specific IgGProtein-specific IgGSelf-antigensImmune response to COVID-19 vaccinationCOVID-19 vaccineAntibody responseResponse to COVID-19 vaccinationT cell expansionSARS-CoV-2-specific antibody responsesAssociated with no improvementLong COVIDAssociated with symptom improvementChest painCirculating cytokinesImmune phenotypeProspective studyImmune featuresTransient improvementPrimary seriesVaccine doseHerpes virusImmune responseSymptom improvementSignificant elevationImpact of COVID-19 vaccinationNirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Mouslmani M, Hooper W, Putrino D, Carr K, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler F, Spertus J, Iwasaki A, Krumholz H. Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet Infectious Diseases 2025, 25: 936-946. PMID: 40188838, DOI: 10.1016/s1473-3099(25)00073-8.Peer-Reviewed Original ResearchPhysical health summary scoreBaseline to dayAdverse eventsNirmatrelvir-ritonavirSARS-CoV-2 infectionDouble-blindStudy drug-related treatment-emergent adverse eventsDrug-related treatment-emergent adverse eventsTreatment-emergent adverse eventsIntention-to-treat populationWeek 6Baseline to week 6Documented SARS-CoV-2 infectionActive liver diseaseEffective pharmacological interventionsLong COVIDAcute medical illnessSafety populationPatient-Reported Outcomes Measurement Information SystemEarly treatment terminationRenal impairmentTreat long-COVIDPlacebo-ControlledEfficacy endpointRandomised controlled trials
2024
Internal Tremors and Vibrations in Long COVID: A Cross-Sectional Study
Zhou T, Sawano M, Arun A, Caraballo C, Michelsen T, McAlpine L, Bhattacharjee B, Lu Y, Khera R, Huang C, Warner F, Herrin J, Iwasaki A, Krumholz H. Internal Tremors and Vibrations in Long COVID: A Cross-Sectional Study. The American Journal Of Medicine 2024, 138: 1010-1018.e14. PMID: 39069199, PMCID: PMC12023347, DOI: 10.1016/j.amjmed.2024.07.008.Peer-Reviewed Original ResearchNew-onset conditionsInternal tremorLong COVID symptomsCOVID symptomsNon-Hispanic whitesCross-sectional studyQuality of lifeVisual analogue scaleWorse healthHealth statusStudy participantsDemographic characteristicsAnalogue scaleOutcome variablesNeurological conditionsLong COVIDMast cell disordersTreatment experienceHealthComorbiditiesSymptomsMedian agePeopleCell disordersThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024, 138: 884-892.e4. PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentLong COVID Characteristics and Experience: A Descriptive Study From the Yale LISTEN Research Cohort
Sawano M, Wu Y, Shah R, Zhou T, Arun A, Khosla P, Kaleem S, Vashist A, Bhattacharjee B, Ding Q, Lu Y, Caraballo C, Warner F, Huang C, Herrin J, Putrino D, Michelsen T, Fisher L, Adinig C, Iwasaki A, Krumholz H. Long COVID Characteristics and Experience: A Descriptive Study From the Yale LISTEN Research Cohort. The American Journal Of Medicine 2024, 138: 712-720.e13. PMID: 38663793, DOI: 10.1016/j.amjmed.2024.04.015.Peer-Reviewed Original ResearchExperiences of peopleHealth statusLong COVIDLower health statusNew-onset conditionsCommunity support servicesNon-Hispanic whitesArray of healthQuality of lifeVisual analogue scaleMental healthPsychological distressPsychological statusDescriptive studyHealthcare systemMedian scoreSupport servicesResearch cohortSocial isolationDemographic characteristicsAnalogue scaleImpact of long COVIDHealthFinancial stressParticipants
2023
Distinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresIL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant
Biswas B, Roy S, Banerjee I, Jana S, Bhattacharjee B, Chakraborty S, Mondal A, Goswami R. IL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant. Heliyon 2023, 9: e16985. PMID: 37292329, PMCID: PMC10238278, DOI: 10.1016/j.heliyon.2023.e16985.Peer-Reviewed Original ResearchViral load patientsCOVID-19 patientsNon-vaccinated patientsViral loadIL-10/IL-6 ratioHyper-inflammatory immune responseMultiple pro-inflammatory cytokinesCT valuesIL-10/IL-6Control groupSwab samplesPro-inflammatory cytokinesRelease of multiple pro-inflammatory cytokinesOral swab samplesUninfected donorsICU supportStatus of vaccinationNasal swab samplesInflammatory indicatorsDisease progressionCytokine markersPatientsNon-vaccinated COVID-19 patientsNasal swabsUninfected individuals
2022
Influence of Sub-Inhibitory Dosage of Cefotaxime on Multidrug Resistant Staphylococcus haemolyticus Isolated from Sick Neonatal Care Unit
Chakraborty M, Bardhan T, Basu M, Bhattacharjee B. Influence of Sub-Inhibitory Dosage of Cefotaxime on Multidrug Resistant Staphylococcus haemolyticus Isolated from Sick Neonatal Care Unit. Antibiotics 2022, 11: 360. PMID: 35326823, PMCID: PMC8944431, DOI: 10.3390/antibiotics11030360.Peer-Reviewed Original ResearchExtracellular DNABiofilm formationS. haemolyticus isolatesBiofilm-forming abilityNon-susceptibilityGenerations of growthSick neonatal care unitCrystal violet assayAntibiotic non-susceptibilityNon-susceptible isolatesS. haemolyticusBiofilm productionNeonatal care unitStaphylococcus haemolyticusDosage of cefotaximeMDR isolatesExtracellular DNA levelsDoses of antibioticsConcentrations of cefotaximeCare of neonatesSub-optimal dosesCTX resistanceSepsis pathogensSub-optimal concentrationsNewborn infants